Pharmaceutical Partnerships

Growth Through Acquisitions

We look for companies with the same culture and ethos as ours, so together we can provide extraordinary service to our customers to benefit the health of all generations.
Contact Us

Galen’s history of acquisitions

Since 1968, Galen has been dedicated to growing in the pharmaceutical industry through strategic acquisitions.

Our acquisition of POA Pharma in 2020 was a major step forward, allowing us to expand into the Nordic region and broaden our product range. This expansion not only increased our presence but also enhanced our product offerings, demonstrating our commitment to innovation and progress in the pharmaceutical sector.

Collaborating with other organisations has encouraged innovation and efficiency, ultimately benefiting patients and healthcare providers.

Our Acquisition Strategy

Expanding into new therapeutic areas
Growing our global footprint
Developing our existing portfolio of products
Providing greater options to patients and healthcare professionals

Acquiring the Right Fit

Our growth strategy includes ambitious expansion plans across new territories and therapeutic areas via acquisition. We continue to look for opportunities that align with our growth strategy.

What Galen looks for in potential acquisitions:

  • Good cultural fit
  • Strong portfolio of late stage or marketed products
  • Global expansion opportunities
  • Established network of contacts
  • Growth potential

What Galen brings to the table in an acquisition:

  • Privately owned company
  • A substantial infrastructure and the support services that come with a multinational organisation
  • Existing network of global distributors
  • Considerable expertise in supporting partners, healthcare professionals and patients
  • Ambitious targets and growth plans for the future

A Brief History of Galen's Acquisitions

1968

Galen was established by Sir Allen McClay

2002

Sir Allen McClay founded the Almac Group

2011

Galen US Inc was established

2020

Galen acquired POA Pharma Scandinavia AB

2023

POA Pharma GmbH was founded

Our Acquisition Process

Initial Contact

Identify potential organisation who are aligned to Galen's vision and values.

Evaluation

Following introductions, a review should be completed on the strategic fit and build a business case for the acquisition.

Negotiation

Negotiate terms and agree on a deal structure, before signing and closing the deal.

Integration

Create an integration strategy and plan to align the organisational objectives and structure and monitor throughout.

Meet our Acquisition Team

Johnny McGaughey

Johnny McGaughey

Head of Business Development
Natasha Guy

Natasha Guy

Business Development Licensing Manager
Aimee Campbell

Aimee Campbell

Business Development Support Manager
Email the Team

About our Recent Acquisition…

"Galen’s long heritage and expertise in delivering valued medicines to the people that need them most, coupled with POA Pharma’s important portfolio, means we have the opportunity to improve the lives of more people affected by a variety of diseases within the Nordic region, and indeed on a truly global scale."
Simon Lawrence

    MAT-GAL-UKI-000245. Date of preparation: November 2024.

    Interested in partnering with us?

    Partner with Galen and be a part of our innovative advancements in the pharmaceutical industry. Contact us to explore acquisition opportunities and see how we can achieve mutual success together.
    Get in touch
    Copyright ©2025 Galen Limited.